MarketResearch.biz delivers in-depth insights on the global biopharmaceutical contract manufacturing market in its upcoming report titled, “Global Biopharmaceutical Contract Manufacturing Market Trends, Applications, Analysis, Growth, and Forecast: 2018 to 2027”. The global biopharmaceutical contract manufacturing market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2027. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global biopharmaceutical contract manufacturing market report has been segmented on the basis of contract type, product type, therapeutic application, and region.
Biopharmaceuticals products have a complex manufacturing process and requires validation and analyses at every steps due to the sensitivity of product. Biopharmaceutical manufacturer are developing various technology that provides greater flexibility, reduced resources for cleaning and validation process and faster turnaround between products and batches which in turn have reduced the capital cost for manufacturing the biopharmaceutical products. Prices for biopharmaceutical products is high owing to the high cost of manufacturing. Furthermore, cost is incurred during storage and distribution of the products as it required specific temperature which add up to the cost of finish product.
Technological advancements by contract manufacturer have aided to increase the effectiveness of medicine, furthermore manufacturer are continuously improving on scalability of the product and adopting various analytical process so as to improve process robustness, these are major factors driving the growth of global biopharmaceutical contract manufacturing market. In addition, demand for biopharmaceutical products is expected to increase over the forecast period owing to a rise of treatments for many orphan diseases which in turn is expected to drive the growth of global biopharmaceutical contract manufacturing market. Moreover, key players are collaborating with contract manufacturer to add innovative products in portfolio which is expected to drive the market growth.
Biopharmaceutical products are sensitive to manufacturer and requires analyses at different scales of production also high investment for setting up advance technology during manufacturing process are major factors restraining the growth of the global biopharmaceutical contract manufacturing market.
North America market dominates the global biopharmaceutical contract manufacturing market in terms of revenue contribution as compared to that of markets in other regions. Europe accounts for second-largest revenue share contribution to the global biopharmaceutical contract manufacturing, followed by markets in Asia Pacific, Latin America, and Middle East & Africa respectively. The market in Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years.
Global biopharmaceutical contract manufacturing market segmentation;
By contract type:
- Active Pharmaceutical Ingredient (API)
- Finish Product
By product type:
- Monoclonal Antibodies
- Recombinant Hormone
By therapeutic applications;
- Autoimmune Diseases
- Metabolic Diseases
- Cardiovascular Diseases
- Infectious Diseases
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn
- ProBioGen AG
- Biomeva GmbH
- Lonza Group AG
- Baxter Pharmaceutical Solutions LLC
- Rentschler Biotechnologie GmbH
- KBI Biopharma Inc.
- Sandoz International GmbH
- WuXi Biologics
- Vetter Pharma International GmbH
- Catalent, Inc.
Request for TOC
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
Request for Customization
Don't just take our word. We are trusted by these great companies!